Patents by Inventor W. Page Faulk

W. Page Faulk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8183208
    Abstract: Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which inhibit the replication of the virus, a cytotoxic antibiotic, an alkylating agent, a plant toxin, and a bacterial mutant toxin. Transferrin or transcobalamin is preferably coupled to the anti-viral agent by means of glutaraldehyde.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: May 22, 2012
    Assignee: Faulk Pharmaceuticals, Inc.
    Inventor: W. Page Faulk
  • Publication number: 20090068104
    Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate has a predetermined ratio of drug molecules to protein molecules that preferentially bind to such cells and a method for making such a conjugate. The method of making the conjugate comprises adding drug molecules to linker molecules in a manner that effectively results in one molecule of drug for each molecule of linker followed by the addition of the drug-linker combination to protein molecules in order to achieve the predetermined ratio of drug molecules to protein molecules.
    Type: Application
    Filed: November 13, 2008
    Publication date: March 12, 2009
    Applicant: Faulk Pharmaceuticals
    Inventor: W. Page FAULK
  • Patent number: 7417023
    Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: August 26, 2008
    Assignee: Faulk Pharmaceuticals, Inc.
    Inventor: W. Page Faulk
  • Patent number: 7101842
    Abstract: Targeting agents such as transferrin and transcobalamin can be conjugated with anti-protozoan drugs for the treatment of protozoan infections. Any suitable anti-protozoan drug can be used, preferably the drug is selected from the group consisting of apoptosis inducing compounds, cytotoxic antibiotics, alkalating agents, plant toxins, and bacterial mutant toxins. The targeting agent is preferably coupled to the antiprotozoan drug by means of glutaraldehyde.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: September 5, 2006
    Assignee: Faulk Pharmaceuticals, Inc.
    Inventor: W. Page Faulk
  • Patent number: 7001991
    Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: February 21, 2006
    Assignee: Faulk Pharmaceuticals, Inc.
    Inventor: W. Page Faulk
  • Publication number: 20040220086
    Abstract: Diseased tissue is treated by contact with a protein that preferentially binds to cells in the diseased tissue, the protein carrying with it a plurality of cell-affecting entities.
    Type: Application
    Filed: April 19, 2004
    Publication date: November 4, 2004
    Inventor: W. Page Faulk
  • Publication number: 20040167061
    Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate has a predetermined ratio of drug molecules to protein molecules that preferentially bind to such cells and a method for making such a conjugate. The method of making the conjugate comprises adding drug molecules to linker molecules in a manner that effectively results in one molecule of drug for each molecule of linker followed by the addition of the drug-linker combination to protein molecules in order to achieve the predetermined ratio of drug molecules to protein molecules.
    Type: Application
    Filed: November 17, 2003
    Publication date: August 26, 2004
    Inventor: W. Page Faulk
  • Publication number: 20040161428
    Abstract: Conjugates of transferrin or transcobalamin with anti-protozoan drugs are useful in the treatment of protozoan infections. Suitable anti-protozoan drugs include apoptosis inducing compounds, a cytotoxic antibiotic, an alkalating agent, a plant toxin, and a bacteria mutant toxin. Transferrin or transcobalamin is preferably coupled to the anti-protozoan drug by means of glutaraldehyde.
    Type: Application
    Filed: November 17, 2003
    Publication date: August 19, 2004
    Inventor: W. Page Faulk
  • Publication number: 20040157767
    Abstract: A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anticancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the conjugate. The targeting protein is preferably transferrin.
    Type: Application
    Filed: November 17, 2003
    Publication date: August 12, 2004
    Inventor: W. Page Faulk
  • Publication number: 20040152071
    Abstract: Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which inhibit the replication of the virus, a cytotoxic antibiotic, an alkylating agent, a plant toxin, and a bacterial mutant toxin. Transferrin or transcobalamin is preferably coupled to the anti-viral agent by means of glutaraldehyde.
    Type: Application
    Filed: November 17, 2003
    Publication date: August 5, 2004
    Inventor: W. Page Faulk